+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446131
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global interleukin inhibitors market.







This report focuses on the interleukin inhibitors market which is experiencing strong growth. The report gives a guide to the interleukin inhibitors market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for interleukin inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Interleukin Inhibitors market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider interleukin inhibitors market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The interleukin inhibitors market section of the report gives context. It compares the interleukin inhibitors market with other segments of the interleukin inhibitors market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, interleukin inhibitors indicators comparison.

Scope


Markets Covered:


  • By Type: IL-17; IL-23; IL-1; IL-5; IL-6; Others
  • By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease; Others
  • By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned:


Sanofi; GlaxoSmithKline; Novartis; Johnson & Johnson; Roche

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Interleukin Inhibitors Market

What is the estimated value of the Global Interleukin Inhibitors Market?

The Global Interleukin Inhibitors Market was estimated to be valued at $19.9 billion in 2021.

What is the growth rate of the Global Interleukin Inhibitors Market?

The growth rate of the Global Interleukin Inhibitors Market is 12.6%, with an estimated value of $32.0 billion by 2025.

What is the forecasted size of the Global Interleukin Inhibitors Market?

The Global Interleukin Inhibitors Market is estimated to be worth $32.0 billion by 2025.

Who are the key companies in the Global Interleukin Inhibitors Market?

Key companies in the Global Interleukin Inhibitors Market include Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Bausch Health.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis

1. Executive Summary2. Interleukin Inhibitors Market Characteristics3. Interleukin Inhibitors Market Trends and Strategies4. Impact Of COVID-19 On Interleukin Inhibitors
5. Interleukin Inhibitors Market Size and Growth
5.1. Global Interleukin Inhibitors Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Interleukin Inhibitors Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Interleukin Inhibitors Market Segmentation
6.1. Global Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others
6.2. Global Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease
  • Others
6.3. Global Interleukin Inhibitors Market, Segmentation by Aplication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Interleukin Inhibitors Market Regional and Country Analysis
7.1. Global Interleukin Inhibitors Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Interleukin Inhibitors Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Interleukin Inhibitors Market
8.1. Asia-Pacific Interleukin Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Interleukin Inhibitors Market
9.1. China Interleukin Inhibitors Market Overview
9.2. China Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Interleukin Inhibitors Market
10.1. India Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Interleukin Inhibitors Market
11.1. Japan Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Interleukin Inhibitors Market
12.1. Australia Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Interleukin Inhibitors Market
13.1. Indonesia Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Interleukin Inhibitors Market
14.1. South Korea Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Interleukin Inhibitors Market
15.1. Western Europe Interleukin Inhibitors Market Overview
15.2. Western Europe Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Interleukin Inhibitors Market
16.1. UK Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Interleukin Inhibitors Market
17.1. Germany Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Interleukin Inhibitors Market
18.4. France Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Interleukin Inhibitors Market
19.1. Eastern Europe Interleukin Inhibitors Market Overview
19.2. Eastern Europe Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Interleukin Inhibitors Market
20.1. Russia Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Interleukin Inhibitors Market
21.1. North America Interleukin Inhibitors Market Overview
21.2. North America Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Interleukin Inhibitors Market
22.1. USA Interleukin Inhibitors Market Overview
22.2. USA Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Interleukin Inhibitors Market
23.1. South America Interleukin Inhibitors Market Overview
23.2. South America Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Interleukin Inhibitors Market
24.1. Brazil Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Interleukin Inhibitors Market
25.1. Middle East Interleukin Inhibitors Market Overview
25.2. Middle East Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Interleukin Inhibitors Market
26.1. Africa Interleukin Inhibitors Market Overview
26.2. Africa Interleukin Inhibitors Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Interleukin Inhibitors Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Interleukin Inhibitors Market Competitive Landscape and Company Profiles
27.1. Interleukin Inhibitors Market Competitive Landscape
27.2. Interleukin Inhibitors Market Company Profiles
27.2.1. Sanofi
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. GlaxoSmithKline
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Novartis
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Johnson & Johnson
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Roche
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Interleukin Inhibitors Pipeline Analysis29. Key Mergers and Acquisitions in the Interleukin Inhibitors Market30. Interleukin Inhibitors Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals.

The global interleukin inhibitors market is expected to grow from $17.73 billion in 2020 to $19.88 billion in 2021 at a compound annual growth rate (CAGR) of 12.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $32 billion in 2025 at a CAGR of 13%.

The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them. These interleukin inhibitors are used for the treatment of autoimmune and inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease

The interleukins inhibitors market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, others and by application into hospital pharmacies, retail pharmacies, online pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

High costs associated with biological therapy are hampering the interleukin inhibitors market. Biologic treatment that has revolutionized the care of psoriasis patients is expensive than the other treatments. The total annual cost ranged from $2,077 to US $13,132 for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient. As of 2020, biologics treatment cost was around $10,000 to $30,000 per year. The higher price of biologics and low healthcare expenditure in developing countries is, therefore, likely to hinder the market growth.

An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses preventing damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval.

Patent expiry of biologic drugs is opening opportunities for biosimilar drugs, which are a cheap alternative. Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx) among others are in development by Mabpharm, NeuClone Pharmaceuticals Ltd, Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biologic therapy, and access to treatment may be limited for several reasons including higher treatment costs. This factor coupled with rapid advances in biotechnology and analytical sciences, which ensure comparability of biosimilars to biologic drugs, drive the trend for biosimilars.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Sanofi
  • GlaxoSmithKline
  • Novartis
  • Johnson & Johnson
  • Roche
  • Eli Lilly
  • AstraZeneca
  • Teva Pharmaceutical
  • Regeneron Pharmaceuticals
  • Bausch Health
Note: Product cover images may vary from those shown

Loading
LOADING...